Search

Displaying results 321 - 330 of 1901 in total
  1. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.

    Categories: Sphingosine 1-phosphate Receptor Modulator, Sphingosine 1 Phosphate Receptor Modulators
  2. Drug

    Butabarbital

    go.drugbank.com/drugs/DB00237
    ApprovedIllicitWithdrawn

    [A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. … [A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613]

  3. Drug

    Beta carotene

    go.drugbank.com/drugs/DB06755
    ApprovedNutraceutical

    [T158] Under the FDA, beta-carotene is considered as a generally recognized as safe substance (GRAS).[L2191]

    Mixtures: BiO-LiFE Anti-FR+Selenium Tablets, Prenatabs FA
  4. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically

    Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Neuroactive Steroid Gamma-Aminobutyric Acid (GABA) A Receptor Positive Modulators
  5. Drug

    Capsaicin

    go.drugbank.com/drugs/DB06774
    ApprovedInvestigational

    The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

  6. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Within Canada and the United States, paritaprevir is currently available in three fixed dose products: Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada). … More specifically, paritaprevir prevents viral replication by inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].

  7. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA Label]. … Ombutasvir is also available as a fixed-dose combination product with [DB09297] and [DB00503] as the FDA- and Health Canada-approved product Technivie.

  8. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    arthritis (RA) in combination with methotrexate. … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

    Categories: Interleukin-6 Receptor Antagonist
  9. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

  10. Drug

    Acetaminophen

    go.drugbank.com/drugs/DB00316
    ApprovedInvestigational

    FDA in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. … [L5786,L5789,L4396] On September 22, 2025, the US FDA initiated a labeling change for acetaminophen products suggesting that the use of acetaminophen by pregnant women may be associated with an increased

    Mixtures: FLUKOL X-TRA, PIM-TRA-KOL FLUInternational brands: Snaplets-FR